Investment advisory firms EcoR1 Capital and Farallon Capital Management led a $110m Series B round in Affinia Therapeutics. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners. Existing investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates also participated in the round. “Gene therapies with novel vectors and regulatory elements have the potential to benefit a broad range of both rare and non-rare diseases. We are impressed with Affinia Therapeutics’ leadership team and scientific progress and are pleased to support the Company at this critical juncture as it brings forth novel gene therapies with the potential to impact a wide range of diseases, giving new hope to patients,” Caroline Stout, EcoR1 Capital Partner.